title: Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy.
abstract: OBJECTIVE
  To clarify clinicopathological similarities and differences between breast carcinomas that achieve pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) and those showing progressive disease (PD) during NAC, we compared pre-NAC clinicopathological characteristics between these tumors.
  
  
  METHODS
  Subjects comprised 32 patients (6%) achieved pCR and 33 patients (7%) showed PD of 494 patients (498 breasts) with stage II or III breast carcinoma who underwent anthracycline-based or taxane chemotherapy or both, followed by surgery, between 2000 and 2006. We compared patient characteristics before NAC, and histomorphology, immunohistochemistry, and molecular subtypes of tumors using pre-NAC biopsy samples. Immunohistochemistry included estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor-2 (HER2), epidermal growth factor receptor (EGFR), cytokeratin 5/6 (CK5/6). Molecular subtypes were defined by ER, PgR, HER2, EGFR, and CK5/6. We compared these factors between pCR and PD using univariate chi (2) testing and multivariate logistic regression analyses.
  
  
  RESULTS
  No significant differences between groups were seen regarding NAC regimens. Solid-tubular carcinoma (53% of pCR, 61% of PD), histological grade 3 (78% of pCR, 79% of PD), ER-status (91% of pCR, 82% of PD), and basal-like subtype (44% of pCR, 58% of PD) were often observed in both groups. In multivariate analyses, lower clinical N stage at diagnosis (P = 0.004) and HER2/ER-PgR- subtype (P = 0.020) were significantly associated with pCR.
  
  
  CONCLUSIONS
  Breast carcinomas achieving pCR or showing PD with NAC have common peculiar characteristics such as solid-tubular carcinoma, high grade, hormone receptor negativity, and basal-like subtype. Conversely, discriminative factors include clinical N stage at diagnosis and HER2/ER-PgR- subtype.
authors.affiliation: Division of Pathology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-10-6, Ariake, Koto-ku, Tokyo, 135-8550, Japan. tomo.osako@jfcr.or.jp
authors.forename: Tomo
authors.initials: T
authors.lastname: Osako
authors.forename: Rie
authors.initials: R
authors.lastname: Horii
authors.forename: Masaaki
authors.initials: M
authors.lastname: Matsuura
authors.forename: Akiko
authors.initials: A
authors.lastname: Ogiya
authors.forename: Kaoru
authors.initials: K
authors.lastname: Domoto
authors.forename: Yumi
authors.initials: Y
authors.lastname: Miyagi
authors.forename: Shunji
authors.initials: S
authors.lastname: Takahashi
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Ito
authors.forename: Takuji
authors.initials: T
authors.lastname: Iwase
authors.forename: Futoshi
authors.initials: F
authors.lastname: Akiyama
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D018943:Anthracyclines / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D017024:Chemotherapy, Adjuvant; D018450:Disease Progression; D000077143:Docetaxel; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D009367:Neoplasm Staging; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D018943:Anthracyclines; D014408:Biomarkers, Tumor; D000077143:Docetaxel; D004317:Doxorubicin; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D043823:Taxoids
references.citation: J Clin Oncol. 1999 Feb;17(2):460-9
references.pmid: 10080586
references.citation: Br J Cancer. 2002 Apr 8;86(7):1041-6
references.pmid: 11953845
references.citation: J Natl Cancer Inst. 2004 Aug 4;96(15):1141-51
references.pmid: 15292386
references.citation: J Clin Oncol. 2003 Jul 1;21(13):2600-8
references.pmid: 12829681
references.citation: Breast. 2007 Dec;16 Suppl 2:S72-7
references.pmid: 17714947
references.citation: J Clin Oncol. 2006 May 1;24(13):2019-27
references.pmid: 16606972
references.citation: Cancer Res. 1990 Nov 1;50(21):7057-61
references.pmid: 2208173
references.citation: Cancer. 2007 Sep 15;110(6):1195-200
references.pmid: 17647266
references.citation: J Natl Cancer Inst Monogr. 2001;(30):96-102
references.pmid: 11773300
references.citation: Breast Cancer. 2005;12 Suppl:S1-27
references.pmid: 16410755
references.citation: Breast Cancer. 2008;15(1):5-7
references.pmid: 18224386
references.citation: Breast Cancer. 2007;14(4):393-400
references.pmid: 17986805
references.citation: Mod Pathol. 2005 Jan;18(1):26-35
references.pmid: 15332092
references.citation: BMC Cancer. 2007 Nov 01;7:203
references.pmid: 17976237
references.citation: J Clin Oncol. 2005 Jun 1;23(16):3676-85
references.pmid: 15738535
references.citation: Eur J Cancer. 2003 May;39(8):1089-96
references.pmid: 12736108
references.citation: Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
references.pmid: 12829800
references.citation: Mod Pathol. 2006 Feb;19(2):264-71
references.pmid: 16341146
references.citation: Clin Cancer Res. 2007 Apr 15;13(8):2329-34
references.pmid: 17438091
references.citation: Jpn J Clin Oncol. 2008 Feb;38(2):99-105
references.pmid: 18270380
references.citation: J Clin Oncol. 1997 Jul;15(7):2483-93
references.pmid: 9215816
references.citation: J Clin Oncol. 2001 Nov 15;19(22):4224-37
references.pmid: 11709566
references.citation: J Clin Oncol. 2002 Mar 15;20(6):1456-66
references.pmid: 11896092
references.citation: Ann Surg Oncol. 2002 Apr;9(3):228-34
references.pmid: 11923128
references.citation: Cancer. 2002 Jun 15;94(12):3107-14
references.pmid: 12115341
references.citation: J Clin Oncol. 2008 Jan 10;26(2):246-52
references.pmid: 18056680
references.citation: Clin Cancer Res. 2004 Aug 15;10(16):5367-74
references.pmid: 15328174
references.citation: Cancer. 2002 Aug 15;95(4):681-95
references.pmid: 12209710
references.citation: Chin Med J (Engl). 2008 Mar 5;121(5):387-91
references.pmid: 18364105
references.citation: J Clin Oncol. 1998 Jan;16(1):93-100
references.pmid: 9440728
references.citation: Cancer. 2005 Jun 1;103(11):2252-60
references.pmid: 15834928
references.citation: Clin Cancer Res. 2005 Aug 15;11(16):5678-85
references.pmid: 16115903
references.citation: Br J Cancer. 2003 May 6;88(9):1339-45
references.pmid: 12778058
references.citation: Gan No Rinsho. 1985 May;Suppl:105-13
references.pmid: 2999462
references.citation: Jpn J Clin Oncol. 1998 Aug;28(8):486-91
references.pmid: 9769782
references.citation: Breast Cancer Res Treat. 2008 Mar;108(2):183-90
references.pmid: 17468948
references.citation: Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
references.pmid: 11553815
references.citation: Histopathology. 1991 Nov;19(5):403-10
references.pmid: 1757079
references.citation: J Clin Oncol. 2003 Nov 15;21(22):4165-74
references.pmid: 14559892
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: J Natl Cancer Inst. 2003 Jan 15;95(2):142-53
references.pmid: 12529347
references.citation: Clin Cancer Res. 2008 Mar 1;14(5):1368-76
references.pmid: 18316557
references.citation: Cancer Res. 2008 Aug 15;68(16):6477-81
references.pmid: 18701468
references.citation: Breast Cancer Res. 2008;10(2):R30
references.pmid: 18380893
references.citation: J Natl Cancer Inst. 2005 Feb 2;97(3):188-94
references.pmid: 15687361
references.citation: J Clin Oncol. 2005 Nov 20;23(33):8331-9
references.pmid: 16293864
references.citation: JAMA. 2006 Jun 7;295(21):2492-502
references.pmid: 16757721
references.citation: J Clin Oncol. 2008 Feb 10;26(5):778-85
references.pmid: 18258986
references.citation: J Clin Oncol. 2008 Mar 10;26(8):1275-81
references.pmid: 18250347